Amgen headquarters in Thousand Oaks. (file photo) Thousand Oaks-based Amgen has received approval from the U.S. Food and Drug Administration for its treatment, Imdelltra, which is used on adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Announced May 16, Amgen said in a press release that Imdelltra
Amgen's new research and development facility in San Francisco. (courtesy photo) Shares of Thousand Oaks-based Amgen gained 12% on May 3, one day after the company disclosed its earnings for the first quarter of 2024 and highlighted the excitement around its weight-loss drug. During the company’s earnings call, Amgen CEO Bob Bradway commented on their
Amgen Chairman and CEO Robert Bradway speaks at a company celebration at its Thousand Oaks headquarters on Oct. 12. (Mike Harris / PCBT Staff) Thousand Oaks-based Amgen has a lot on the horizon as it nears the end of fiscal year 2023, with the company yet again beating analysts' expectations, this time in the third
Thousand Oaks-based Amgen filed 126 patents over the last year, dethroning Santa Barbara-based Sonos which led the tri-county the previous two years. Overall, however, the thousands of patents granted to companies along the Central Coast once again highlighted the variety of companies. A Business Times analysis of nearly 5,000 patents granted to the region’s inventors
Amgen's new research and development facility in San Francisco. (courtesy photo) The Federal Trade Commission has put a pause on its lawsuit against Thousand Oaks-based Amgen’s acquisition of Horizon Therapeutics to allow time for the FTC to consider a settlement. If a settlement is agreed to, then this legal saga between Amgen and the FTC